Sarepta Therapeutics (NASDAQ:SRPT) Given New $200.00 Price Target at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its target price reduced by Royal Bank of Canada from $226.00 to $200.00 in a research report issued on Friday, The Fly reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price points to a potential upside of 63.01% from the company’s previous close.

SRPT has been the subject of several other reports. BTIG Research increased their price objective on shares of Sarepta Therapeutics from $125.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, December 22nd. Oppenheimer decreased their price objective on shares of Sarepta Therapeutics from $180.00 to $150.00 and set an “outperform” rating for the company in a report on Thursday, March 9th. StockNews.com assumed coverage on shares of Sarepta Therapeutics in a report on Thursday. They set a “hold” rating for the company. Robert W. Baird raised their target price on shares of Sarepta Therapeutics from $152.00 to $202.00 and gave the stock an “outperform” rating in a report on Wednesday, March 1st. Finally, Mizuho restated a “buy” rating and set a $160.00 target price on shares of Sarepta Therapeutics in a report on Friday. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $165.88.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $122.69 on Friday. The firm’s 50 day moving average is $129.49 and its two-hundred day moving average is $120.17. The company has a debt-to-equity ratio of 4.01, a quick ratio of 3.80 and a current ratio of 4.13. Sarepta Therapeutics has a 52 week low of $61.28 and a 52 week high of $159.84.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.04. The business had revenue of $258.43 million during the quarter, compared to analysts’ expectations of $250.51 million. Sarepta Therapeutics had a negative net margin of 75.40% and a negative return on equity of 117.29%. The business’s revenue was up 28.3% on a year-over-year basis. During the same period last year, the firm posted ($1.42) earnings per share. As a group, analysts expect that Sarepta Therapeutics will post -4.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in SRPT. FourThought Financial LLC lifted its position in Sarepta Therapeutics by 43.5% in the 3rd quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares in the last quarter. AQR Capital Management LLC lifted its position in Sarepta Therapeutics by 3.5% in the 4th quarter. AQR Capital Management LLC now owns 2,826 shares of the biotechnology company’s stock worth $366,000 after buying an additional 95 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in Sarepta Therapeutics by 16.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 685 shares of the biotechnology company’s stock worth $89,000 after buying an additional 97 shares in the last quarter. Utah Retirement Systems lifted its position in Sarepta Therapeutics by 0.7% in the 3rd quarter. Utah Retirement Systems now owns 14,971 shares of the biotechnology company’s stock worth $1,654,000 after buying an additional 100 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its position in Sarepta Therapeutics by 2.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 4,250 shares of the biotechnology company’s stock worth $470,000 after buying an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.